Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- INDV
- Price
- 34.75
- Stock movement up
- +0.17 (0.49%)
- Company name
- Indivior PLC Ordinary Shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 4.34B
- Ent value
- 5.52B
- Price/Sales
- 3.68
- Price/Book
- -
- Div yield
- 2.73%
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 26.17
- Forward P/E
- 11.63
- PEG
- -
- EPS growth
- -55.78%
- 1 year return (CAGR)
- 244.74%
- 3 year return (CAGR)
- 12.89%
- 5 year return (CAGR)
- 77.45%
- 10 year return (CAGR)
- 32.91%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
INDV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 26.17 |
| Price to OCF | 22.39 |
| Price to FCF | 32.19 |
| Price to EBITDA | 13.75 |
| EV to EBITDA | 17.48 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.68 |
| Price to Book | - |
| EV to Sales | 4.68 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 125.02M |
| EPS (TTM) | 1.29 |
| FCF per share (TTM) | 1.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.18B |
| Gross profit (TTM) | 978.00M |
| Operating income (TTM) | 277.00M |
| Net income (TTM) | 166.00M |
| EPS (TTM) | 1.29 |
| EPS (1y forward) | 2.99 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 82.81% |
| Operating margin (TTM) | 23.45% |
| Profit margin (TTM) | 14.06% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 445.00M |
| Net receivables | 272.00M |
| Total current assets | 922.00M |
| Goodwill | 0.00 |
| Intangible assets | 2.00M |
| Property, plant and equipment | 260.00M |
| Total assets | 1.42B |
| Accounts payable | 41.00M |
| Short/Current long term debt | 356.00M |
| Total current liabilities | 965.00M |
| Total liabilities | 1.62B |
| Shareholder's equity | -207.00M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 194.08M |
| Capital expenditures (TTM) | 59.10M |
| Free cash flow (TTM) | 134.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | 11.72% |
| Return on Invested Capital | 132.80% |
| Cash Return on Invested Capital | 107.99% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 34.61 |
| Daily high | 35.29 |
| Daily low | 34.52 |
| Daily Volume | 1.37M |
| All-time high | 36.60 |
| 1y analyst estimate | 45.57 |
| Beta | 1.14 |
| EPS (TTM) | 1.29 |
| Dividend per share | 0.95 |
| Ex-div date | 16 Jun 2016 |
| Next earnings date | 26 Feb 2026 |
Downside potential
Loading...
Downside potential data
| INDV | S&P500 | |
| Current price drop from All-time high | -5.05% | -1.82% |
| Highest price drop | -93.82% | -56.47% |
| Date of highest drop | 11 Apr 2019 | 9 Mar 2009 |
| Avg drop from high | -40.05% | -10.84% |
| Avg time to new high | 21 days | 12 days |
| Max time to new high | 1097 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
4.34B
Marketcap category
Mid-cap
Description
Indivior Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Employees
1030
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
Semi-annual
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page